GlassScriptPhysician profile
Stephanie H Howard
NPI 1083903306
$18,205.89
in general payments reported to CMS, 2019-2025
36 companies · $934 in 2025
The $934 reported for 2025 was more than what 79% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,636 · 2022: $5,502 · 2023: $4,963 · 2024: $1,172 · 2025: $934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,849 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,490 · Education: $388 · Travel and Lodging: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,849.09 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,490.00 |
| Education | $387.93 |
| Travel and Lodging | $341.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $7,084.19 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $3,605.36 | 2023-2025 | Myfembree, Gemtesa |
| Abbvie INC. | $1,164.10 | 2021-2025 | |
| Novo Nordisk INC | $954.55 | 2021-2025 | Wegovy, Saxenda |
| Astellas Pharma US INC | $875.40 | 2021-2025 | Veozah |
| Mayne Pharma Commercial LLC | $811.19 | 2021-2025 | |
| Therapeuticsmd, INC. | $426.32 | 2021-2022 | |
| Exeltis, USA INC. | $368.22 | 2021-2025 | Slynd |
| Currax Pharmaceuticals LLC | $318.62 | 2021-2025 | Contrave, Onzetra Xsail |
| Myovant Sciences INC. | $317.74 | 2021-2022 | |
| Ascend Therapeutics US, LLC | $304.70 | 2021-2023 | |
| Millicent US INC | $254.83 | 2021-2025 | Femlyv, Intrarosa, Femring |
| Avion Pharmaceuticals | $246.98 | 2021-2023 | Balcoltra |
| Aspira Women'S Health INC | $235.14 | 2022-2023 | Ova1 |
| Biohaven Pharmaceuticals, INC. | $187.31 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $179.84 | 2021-2025 | Zepbound |
| Exact Sciences Corporation | $120.55 | 2023-2024 | Cologuard Collection Kit |
| Mycovia Pharmaceuticals, INC. | $115.46 | 2022-2023 | Vivjoa |
| Alfasigma USA, INC. | $100.50 | 2022 | |
| Evofem Biosciences, INC. | $62.49 | 2021-2022 | |
| Daiichi Sankyo INC. | $60.38 | 2021-2022 | |
| Agile Therapeutics, INC. | $56.94 | 2021-2023 | Twirla |
| Takeda Pharmaceuticals U.S.A., INC. | $48.87 | 2021-2022 | |
| Scynexis, INC. | $48.45 | 2022 | |
| Lupin INC. | $44.62 | 2021 | |
| Hologic Sales and Service, LLC | $28.73 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.02 | 2025 | |
| Shield Therapeutics INC | $24.10 | 2024 | |
| Astellas Pharma Global Development | $22.50 | 2024 | Veozah |
| Sage Therapeutics, LLC | $19.32 | 2024 | |
| Organon LLC | $17.88 | 2023 | Nexplanon |
| Biohaven Pharmaceutical Holding Company LTD. | $17.42 | 2022 | |
| Radius Health, INC. | $15.89 | 2021 | |
| Ibsa Pharma INC. | $15.84 | 2023 | Tirosint, Licart |
| Dysis Medical, INC. | $12.73 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.